Literature DB >> 26452714

SMIM1 is a type II transmembrane phosphoprotein and displays the Vel blood group antigen at its carboxyl-terminus.

Lionel Arnaud1, Liam P Kelley2, Virginie Helias3, Jean-Pierre Cartron3, Bryan A Ballif4.   

Abstract

Disruption of SMIM1, encoding small integral membrane protein 1, is responsible for the Vel-negative blood type, a rare but clinically-important blood type. However, the exact nature of the Vel antigen and how it is presented by SMIM1 are poorly understood. Using mass spectrometry we found several sites of phosphorylation in the N-terminal region of SMIM1 and we found the initiating methionine of SMIM1 to be acetylated. Flow cytometry analyses of human erythroleukemia cells expressing N- or C-terminally Flag-tagged SMIM1, several point mutants of SMIM1, and a chimeric molecule between Kell and SMIM1 demonstrated that SMIM1 carries the Vel antigen as a type II membrane protein with a predicted C-terminal extracellular domain of only 3-12 amino acids.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood group; Mass spectrometry; Phosphorylation; Small integral membrane protein; Type II membrane protein

Mesh:

Substances:

Year:  2015        PMID: 26452714      PMCID: PMC4664579          DOI: 10.1016/j.febslet.2015.09.029

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  The GxxxG motif: a framework for transmembrane helix-helix association.

Authors:  W P Russ; D M Engelman
Journal:  J Mol Biol       Date:  2000-02-25       Impact factor: 5.469

2.  [New blood factor: Vel].

Authors:  L N SUSSMAN; E B MILLER
Journal:  Rev Hematol       Date:  1952

3.  Topology of eukaryotic type II membrane proteins: importance of N-terminal positively charged residues flanking the hydrophobic domain.

Authors:  G D Parks; R A Lamb
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

Review 4.  Secreted protein kinases.

Authors:  Vincent S Tagliabracci; Lorenzo A Pinna; Jack E Dixon
Journal:  Trends Biochem Sci       Date:  2012-12-29       Impact factor: 13.807

5.  ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis.

Authors:  Virginie Helias; Carole Saison; Bryan A Ballif; Thierry Peyrard; Junko Takahashi; Hideo Takahashi; Mitsunobu Tanaka; Jean-Charles Deybach; Hervé Puy; Maude Le Gall; Camille Sureau; Bach-Nga Pham; Pierre-Yves Le Pennec; Yoshihiko Tani; Jean-Pierre Cartron; Lionel Arnaud
Journal:  Nat Genet       Date:  2012-01-15       Impact factor: 38.330

6.  Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.

Authors:  Carole Saison; Virginie Helias; Bryan A Ballif; Thierry Peyrard; Hervé Puy; Toru Miyazaki; Sébastien Perrot; Muriel Vayssier-Taussat; Mauro Waldner; Pierre-Yves Le Pennec; Jean-Pierre Cartron; Lionel Arnaud
Journal:  Nat Genet       Date:  2012-01-15       Impact factor: 38.330

7.  Statistical analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions.

Authors:  A Senes; M Gerstein; D M Engelman
Journal:  J Mol Biol       Date:  2000-02-25       Impact factor: 5.469

8.  Homozygosity for a null allele of SMIM1 defines the Vel-negative blood group phenotype.

Authors:  Jill R Storry; Magnus Jöud; Mikael Kronborg Christophersen; Britt Thuresson; Bo Åkerström; Birgitta Nilsson Sojka; Björn Nilsson; Martin L Olsson
Journal:  Nat Genet       Date:  2013-04-07       Impact factor: 38.330

9.  SMIM1 underlies the Vel blood group and influences red blood cell traits.

Authors:  Ana Cvejic; Lonneke Haer-Wigman; Jonathan C Stephens; Pim van der Harst; C Ellen van der Schoot; Willem H Ouwehand; Cornelis A Albers; Myrto Kostadima; Peter A Smethurst; Mattia Frontini; Emile van den Akker; Paul Bertone; Ewa Bielczyk-Maczyńska; Samantha Farrow; Rudolf Sn Fehrmann; Alan Gray; Masja de Haas; Vincent G Haver; Gregory Jordan; Juha Karjalainen; Hindrik Hd Kerstens; Graham Kiddle; Heather Lloyd-Jones; Malcolm Needs; Joyce Poole; Aicha Ait Soussan; Augusto Rendon; Klaus Rieneck; Jennifer G Sambrook; Hein Schepers; Herman H W Silljé; Botond Sipos; Dorine Swinkels; Asif U Tamuri; Niek Verweij; Nicholas A Watkins; Harm-Jan Westra; Derek Stemple; Lude Franke; Nicole Soranzo; Hendrik G Stunnenberg; Nick Goldman
Journal:  Nat Genet       Date:  2013-04-07       Impact factor: 38.330

10.  Disruption of SMIM1 causes the Vel- blood type.

Authors:  Bryan A Ballif; Virginie Helias; Thierry Peyrard; Cécile Menanteau; Carole Saison; Nicole Lucien; Sébastien Bourgouin; Maude Le Gall; Jean-Pierre Cartron; Lionel Arnaud
Journal:  EMBO Mol Med       Date:  2013-04-15       Impact factor: 12.137

View more
  4 in total

1.  Fyn-dependent phosphorylation of PlexinA1 and PlexinA2 at conserved tyrosines is essential for zebrafish eye development.

Authors:  Riley M St Clair; Sarah E Emerson; Kristen P D'Elia; Marion E Weir; Anna M Schmoker; Alicia M Ebert; Bryan A Ballif
Journal:  FEBS J       Date:  2017-11-17       Impact factor: 5.542

2.  International society of blood transfusion working party on red cell immunogenetics and terminology: report of the Seoul and London meetings.

Authors:  J R Storry; L Castilho; Q Chen; G Daniels; G Denomme; W A Flegel; C Gassner; M de Haas; C Hyland; M Keller; C Lomas-Francis; J M Moulds; N Nogues; M L Olsson; T Peyrard; C E van der Schoot; Y Tani; N Thornton; F Wagner; S Wendel; C Westhoff; V Yahalom
Journal:  ISBT Sci Ser       Date:  2016-06-27

Review 3.  SMIM1 at a glance; discovery, genetic basis, recent progress and perspectives.

Authors:  Yaw Aniweh; Prince B Nyarko; Evelyn Quansah; Laty Gaye Thiam; Gordon A Awandare
Journal:  Parasite Epidemiol Control       Date:  2019-03-06

Review 4.  Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework.

Authors:  Sebastià Galmés; Francisca Serra; Andreu Palou
Journal:  Nutrients       Date:  2020-09-08       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.